Bimekizumab improves signs and symptoms of active ankylosing spondylitis: 24-week results from the phase 3 BE MOBILE 2 study

Authors
Category Primary study
ConferenceInternational Journal of Rheumatic Diseases
Year 2023
This article has no abstract
Epistemonikos ID: dbf67e1cf5a15b3e5b1295f09df6201bf29876c5
First added on: Apr 30, 2026